*November 2023* This is a very interesting video presentation consisting of lung cancer experts and EGFR Resisters co-founder Jill Feldman discussing the treatment options after osimertinib (Tagrisso) faillure. It covers: Importance of liquid and tissue biopsies to check for new mutations chemo is standard of care amivantamab +lazertinib ADCs clinical…

*November 2023* In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non–small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed plus either…

*November 2023* First-line combination treatment regimens are improving progression-free survival (PFS) rates in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to Julia Rotow, MD.1 Prior to November 2023, the main first-line therapy utilized for the treatment of patients with EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase…

*November 2023* Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer. Listen here.  

*December 2023* This new on-demand educational webinar featuring oncology experts (Drs. Balaz Halmos and Julie Rotow) and patient advocates (Ivy Elkins and Jill Feldman) discusses the therapeutic landscape of uncommon EGFR alterations within NSCLC as well as current clinical trials aimed at advancing therapeutic options in this space. Watch video here.  

*November 2023* Earlier this month, 15 young EGFR lung cancer investigators from the U.S., along with a panel of expert mentor judges and patient advocates, gathered together for our 5th annual EGFR Resisters Research Summit. Congratulations to the trainee research award winners. Taking 3rd place was Dr. Marie Dreyer with her…

*October 2023* Sandip P. Patel, MD discusses treatment options available for patients with EGFR-mutant NSCLC who progress on  EGFR TKIs and platinum-based chemotherapy. Watch video here.  

*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…

*October 2023* PURPOSE In the treatment of non-small cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody following tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed…